Company intelligence / Profile preview

All Life Biotechnology

Ownership: Private
Employees: ~120
Development stage: Phase 2

Overview

All Life Group has multiple CAR-NK cell therapy candidates in preclinical and Phase 1/2 clinical trials targeting various cancers including leukemia, multiple myeloma, prostatic cancer, and ovarian cancer.

Therapeutic areas: Oncology
Modalities: Cellular EngineeringInduced Pluripotent Stem Cells (iPSC)Chimeric Antigen Receptor (CAR)
Industry: Biotech

Drug pipeline

2 assets

ALLLIFE CAR-NK BCMA

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on All Life Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on All Life Biotechnology.

Explore the full profile